Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
July 2011, Vol 2, No 4
July 2011, Vol 2, No 4
New End Points Create Novel Challenges for Health Plans in Oncology Drug Management
By
James T. Kenney, RPh, MBA
Commentary
,
Value Peer-spectives
July 2011, Vol 2, No 4
The management of complex oncology drugs in pharmacy and in medical benefits presents unique challenges for all parties who seek cost-effective, positive clinical outcomes for patients with cancer. New therapies are offering the exciting prospect of improved outcomes, prolonged life, and, in some cases, a cure for specific diseases.
Read Article
The Impact of Therapy Type on Clinical Fragmentation in Oncology Care
By
Wayne Kuznar
Oncology
July 2011, Vol 2, No 4
Fragmentation in oncology care significantly influences physicians’, payers’, and patients’ understanding of how cancer therapies lead to improved quality of care.
Read Article
Medical and Pharmacy Directors’ Strategies to Improve Cancer Care Management
By
Wayne Kuznar
Cancer Care
,
Personalized Medicine
July 2011, Vol 2, No 4
Implementing path - ways to sustain community oncology and offering additional nursing and care management models are recent strategies being adopted by various practices and payers to reduce the medical and pharmacy costs in cancer management and improve the quality of care.
Read Article
Implications of Healthcare Reform for Oncologists and Cancer Care
Cancer Care
,
Health Policy
,
Policies & Guidelines
,
Personalized Medicine
July 2011, Vol 2, No 4
The healthcare reform legislation involves many potential issues that can affect oncology, for example, how minimum benefits are defined. First, there are required minimum benefits that all health plans and other insurers have to meet, and we have to make sure that cancer care is included.
Read Article
Oncology Pharmacy as a Specialty
By
Wayne Kuznar
Oncology
July 2011, Vol 2, No 4
An expanding role for oncology pharmacy in the optimization of cancer care is likely to emerge over the next 3 to 5 years, as payers seek better outcomes for their money.
Read Article
Global Fees, ACOs, and New Reimbursement Trends Will Influence Medicare’s Future
Health Economics
July 2011, Vol 2, No 4
Growth in Medicare Part B spending, increasing roles in specialty pharmacy, formation of accountable care organizations (ACOs), and bundling of payments for care are all anticipated trends in the Medicare and reimbursement arenas.
Read Article
Oncology Drug Reimbursement and Administration Benchmarks
By
Wayne Kuznar
Reimbursement
July 2011, Vol 2, No 4
Read Article
Patient Navigation and Patient Assistance Programs in Oncology
By
Wayne Kuznar
Patient Navigation
,
Policies & Guidelines
July 2011, Vol 2, No 4
The medically under - served population needs easier access to healthcare and tools that provide a seamless transition between all phases of the treatment process, from screening through therapy and survivorship.
Read Article
Oncologists Face Economic Challenges while Improving Patient Care
Practice Management
,
Value Peer-spectives
July 2011, Vol 2, No 4
The estimated cost for physician practices to interact with health insurance plans is $23 billion to $31 billion annually, according to a 2009 national survey conducted by Casalino and colleagues (Health Aff. 2009;28:w533-w543).
Read Article
The Crisis in Cancer Care
By
Ted Okon, MBA
Cancer Care
,
Community Oncology
,
Personalized Medicine
July 2011, Vol 2, No 4
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma